Abi-Dargham Anissa
From the Division of Translational Imaging, Department of Psychiatry, Columbia University and New York State Psychiatric Institute, New York.
J Clin Psychiatry. 2014 Nov;75(11):e31. doi: 10.4088/JCP.13078tx2c.
Schizophrenia is a chronic, often disabling illness that affects approximately 24 million people worldwide. Unfortunately, while the majority of first-episode schizophrenia patients respond well to initial antipsychotic treatment, less than 1 in 5 will maintain recovery over 2 to 5 years, and most will experience at least 1 relapse. Dopamine dysfunction helps to explain the positive symptoms experienced by patients with schizophrenia, and targeting these pathways has made current antipsychotics effective treatments for this condition. However, these agents primarily manage the positive symptoms of the disorder, while negative and cognitive symptoms can persist. More treatments are needed that comprehensively address all presentations of the disorder.
精神分裂症是一种慢性且往往会导致残疾的疾病，全球约有2400万人受其影响。不幸的是，虽然大多数首发精神分裂症患者对初始抗精神病药物治疗反应良好，但不到五分之一的患者在2至5年内能够维持康复状态，而且大多数患者至少会经历一次复发。多巴胺功能障碍有助于解释精神分裂症患者所经历的阳性症状，针对这些途径使目前的抗精神病药物成为治疗这种疾病的有效方法。然而，这些药物主要控制该疾病的阳性症状，而阴性和认知症状可能会持续存在。需要更多能够全面解决该疾病所有症状表现的治疗方法。
